CVS to Pay $315M for Illegally Dispensing Opioids and Defrauding Federal Health Programs

CVS Pharmacy has agreed to a $315M settlement over unlawful opioid prescription filling and false claims to Medicare. A whistleblower suit triggered the case.

CVS Settles for $315 Million Over Unlawful Opioid Dispensing and Medicare Fraud

CVS Pharmacy Inc. has agreed to pay $315 million to resolve federal allegations that the Rhode Island-based pharmacy chain illegally filled opioid prescriptions and billed the costs to Medicare and other federal healthcare programs, DOJ Justice News reports. The conduct spans more than a decade — from October 17, 2013 through December 2, 2025.

The settlement resolves allegations that CVS violated both the Controlled Substances Act (CSA) and the False Claims Act (FCA) by knowingly dispensing prescriptions that lacked a legitimate medical purpose, were not valid, or were not issued in the usual course of professional practice.

Dangerous Quantities and "Trinity" Combinations

According to the government's complaint, filed December 13, 2024, in the U.S. District Court for the District of Rhode Island, CVS dispensed excessive and dangerous quantities of opioids, filled opioid prescriptions ahead of schedule, and processed so-called "trinity" prescriptions — a high-risk and widely abused combination of an opioid, a benzodiazepine, and a muscle relaxant.

CVS pharmacists also allegedly filled prescriptions issued by "pill mill" prescribers — practitioners who wrote large volumes of controlled substance prescriptions without any legitimate medical basis. The government contends that pharmacists proceeded despite clear red flags suggesting the prescriptions were invalid or medically unnecessary. Many of those prescriptions were subsequently billed to and reimbursed by federal health programs.

Corporate Pressure Over Patient Safety

Investigators further alleged that CVS's violations were not incidental but structural. The complaint states that corporate-imposed performance metrics, incentive compensation structures, and staffing policies put profits ahead of patient safety. CVS allegedly employed too few pharmacists to meet legal obligations and internal targets simultaneously, and its internal policies reportedly prevented pharmacists from sharing information with colleagues about prescribers flagged as problematic.

Associate Attorney General Stanley E. Woodward Jr. said the settlement "holds bad actors accountable for their fraudulent activities" and that "Americans are safer because of it."

Assistant Attorney General Brett A. Shumate of the Justice Department's Civil Division said the agreement requires CVS to implement additional safeguards ensuring that controlled substances "are dispensed only when medically appropriate," including proactive monitoring of opioid prescribing patterns.

First Assistant U.S. Attorney Charles C. Calenda for the District of Rhode Island pointed to the broader impact of the case. "The opioid epidemic has affected families and communities across Rhode Island and throughout the nation," Calenda said. "Pharmacies that dispense controlled substances must maintain effective compliance systems to identify and respond to warning signs that prescriptions may be unlawful or medically unnecessary."

DEA Agreement and New Compliance Requirements

Beyond the monetary penalty, CVS has entered into a memorandum of agreement with the Drug Enforcement Administration (DEA) governing its future obligations in dispensing controlled substances. Under that agreement, CVS must establish a hotline — accessible to both employees and the public — for reporting suspected illegal dispensing, proactively monitor dispensing patterns at its pharmacies, and create a formal process for evaluating prescribers suspected of illegal prescribing.

DEA Assistant Administrator Cheri Oz said the settlement "highlights DEA's commitment to protecting the health and safety of Americans while holding CVS accountable for dispensing unlawful prescriptions and endangering the public." Oz added that the agency would "continue to work closely with law enforcement, regulatory agencies, and the healthcare community to prevent the misuse of controlled substances."

Acting Deputy Inspector General for Investigations Scott J. Lampert of the U.S. Department of Health and Human Services Office of Inspector General said the allegations pointed to warning signs "that should never be overlooked." Lampert stated that HHS-OIG "will not tolerate conduct that jeopardizes lives."

Whistleblower Triggered the Case

The civil settlement resolves a lawsuit originally filed by Hillary Estright, a former CVS employee, under the whistleblower provision of the False Claims Act. That provision allows private individuals to bring suit on behalf of the United States and receive a share of any financial recovery. The United States subsequently intervened and took over the case. The amount Estright will ultimately receive has not yet been determined. The qui tam case is captioned United States ex rel. Hillary Estright v. CVS Health Corporation, et al., No. 22-cv-00222 (D.R.I.).

Source: DOJ Justice News